Theravance Biopharma (TBPH) Total Debt (2018 - 2022)

Theravance Biopharma (TBPH) has 5 years of Total Debt data on file, last reported at $396.1 million in Q2 2022.

• On a quarterly basis, Total Debt rose 3.69% year-over-year to $396.1 million in Q2 2022; TTM through Jun 2022 was $396.1 million, a 3.69% increase from a year earlier, with the FY2021 full-year figure at $388.3 million, down 1.0% from the prior year.
• Total Debt for Q2 2022 stood at $396.1 million, up from $393.2 million in the prior quarter.
• Over the last five years, Total Debt for TBPH reached as high as $396.1 million in Q2 2022 and fell as low as $229.2 million in Q4 2019.
• Historically, Total Debt has averaged $334.0 million across 5 years, with a median of $382.0 million in 2021.
• Across the five-year window, Total Debt jumped 71.16% in 2020 and declined 1.0% in 2021, its largest moves.
• Year by year, Total Debt stood at $229.5 million in 2018, then retreated by 0.17% to $229.2 million in 2019, then soared by 71.16% to $392.2 million in 2020, then decreased by 1.0% to $388.3 million in 2021, then grew by 2.02% to $396.1 million in 2022.
• Per Business Quant data, the three most recent Total Debt figures were $396.1 million in Q2 2022, $393.2 million in Q1 2022, and $388.3 million in Q4 2021.